RUNX1 and acute myeloid leukemia: Kappala et al. in South Africa using a microarray-based assessment of molecular variables on AML patients noted that 5.7% had inv (6)/t (16; 16) (p13; q22), 11.3% had t (8; 21) (q22; q22), 3.8% had t (15; 17) (q24; q21), 1.9% had double mutant CEBPA, 9.4% had NPM1-ABD mutations and 18.9% had a high expression of EVI1. NPM1 mutations were reported at a lower frequency whereas EVI1 over expression occurred at a higher frequency compared to world data, which would indicate age and racial differences (Kappala et al., 2017).